As of 2026-09-12, the Intrinsic Value of Keros Therapeutics Inc (KROS) is 13.06 USD. This KROS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 11.08 USD, the upside of Keros Therapeutics Inc is 17.90%.
The range of the Intrinsic Value is 13.05 - 13.06 USD
Based on its market price of 11.08 USD and our intrinsic valuation, Keros Therapeutics Inc (KROS) is undervalued by 17.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 13.05 - 13.06 | 13.06 | 17.9% |
| DCF (Growth 10y) | 13.06 - 13.04 | 13.05 | 17.8% |
| DCF (EBITDA 5y) | 14.07 - 14.25 | 14.16 | 27.8% |
| DCF (EBITDA 10y) | 13.83 - 14.07 | 13.94 | 25.8% |
| Fair Value | -21.01 - -21.01 | -21.01 | -289.62% |
| P/E | (97.91) - 0.39 | (55.52) | -601.1% |
| EV/EBITDA | (69.21) - 15.23 | (28.75) | -359.5% |
| EPV | (40.50) - (57.20) | (48.85) | -540.9% |
| DDM - Stable | (25.13) - (76.12) | (50.63) | -556.9% |
| DDM - Multi | 0.04 - 0.11 | 0.06 | -99.4% |
| Market Cap (mil) | 219.27 |
| Beta | 1.47 |
| Outstanding shares (mil) | 19.79 |
| Enterprise Value (mil) | -38.33 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.34% |
| Cost of Debt | 5.00% |
| WACC | 8.65% |